Featured Research

from universities, journals, and other organizations

'Female Sex Hormone' Protects Against Hearing Loss In Females And Males

Date:
March 5, 2008
Source:
Journal of Clinical Investigation
Summary:
The "female sex hormone" estradiol is present in both men and women. It plays various roles in addition to its gender-specific ones, including having effects on the hearing (auditory) system. In a new study, mice deficient in the estrogen receptor beta exhibited reduced recovery from auditory trauma, and treatment with ER beta-binding drugs protected mice from auditory damage, leading to the suggestion that these data might enable the development of new treatments for hearing loss.

The "female sex hormone" estradiol is present in both men and women, and is generated from testosterone in men by the protein aromatase.

Estradiol plays various roles in addition to its gender-specific ones, including having effects on the hearing (auditory) system.

In a new study, Barbara Canlon and colleagues at the Karolinska Institute in Stockholm, Sweden, investigated the role of estradiol-binding proteins, known as estrogen receptors, in response to auditory damage by examining hearing loss recovery in mice with deficiencies in various estrogen receptors.

They found that mice deficient in only the estrogen receptor ER-beta had reduced recovery from auditory trauma, and that treatment with ER-beta binding drugs protected mice from auditory damage.

Furthermore, not only was ER-beta found in the ears of both male and female mice, but levels of the nerve-protecting protein BDNF were reduced in mice that lacked either ER-beta or aromatase.

The authors therefore concluded that this identification of an auditory-protective role for the estrogen receptor ER-beta may enable the development of new treatments for hearing loss.

The journal article is entitled Estrogen receptor beta protects against acoustic trauma in mice.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Cite This Page:

Journal of Clinical Investigation. "'Female Sex Hormone' Protects Against Hearing Loss In Females And Males." ScienceDaily. ScienceDaily, 5 March 2008. <www.sciencedaily.com/releases/2008/03/080303190640.htm>.
Journal of Clinical Investigation. (2008, March 5). 'Female Sex Hormone' Protects Against Hearing Loss In Females And Males. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2008/03/080303190640.htm
Journal of Clinical Investigation. "'Female Sex Hormone' Protects Against Hearing Loss In Females And Males." ScienceDaily. www.sciencedaily.com/releases/2008/03/080303190640.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins